Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales.

Abbott Laboratories has won a legal case claiming its Similac infant formula caused the death of a baby from necrotizing ...

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults ...

Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the ...

The court said D.B.'s parents could not meet the threshold for a product liability claim under Louisiana's Products Liability ...

A federal judge handed Abbott Laboratories another win this week in its yearslong battle over the safety of its formulas for babies born prematurely — a decision that could have implications for ...

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that could trigger new tariffs.

According to Benzinga Pro, Abbott Laboratories's peer group average for short interest as a percentage of float is 5.57%, ...

The fate of hundreds of pending cases against Abbott and Mead Johnson hang in the balance with the latest dismissal.

Abbott Laboratories Inc. convinced a federal judge that there wasn’t a feasible alternative design to a form of infant formula that parents said caused a fatal disease to their preterm child.

Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month.

Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from ...